Page 4 - Solid Tumor News Today

BASEL, Switzerland, BEIJING, & CAMBRIDGE, Mass., August 02, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results from the second quarter of 2023 and business highlights.

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

/PRNewswire/ -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and...

Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and...

DUBLIN--(BUSINESS WIRE)--The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.The global MRD testing market is projected to reach $6.67 billion by 2033...

Among 172 patients with untreated advanced solid tumors, all of them had actionable alterations, and 109 had druggable alterations.

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...

CAR-T therapy is now seeing expansion for use in cancer treatment. Sino Biological produces a large range of promising target antigens for use in the cell therapy of solid tumors.